Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP309473.RABMbVfMkRilsL8AoJLv0eUnW-EU4u8YKyuSCmyHsU9k4130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP309473.RABMbVfMkRilsL8AoJLv0eUnW-EU4u8YKyuSCmyHsU9k4130_assertion type Assertion NP309473.RABMbVfMkRilsL8AoJLv0eUnW-EU4u8YKyuSCmyHsU9k4130_head.
- NP309473.RABMbVfMkRilsL8AoJLv0eUnW-EU4u8YKyuSCmyHsU9k4130_assertion description "[In view of these findings, the anti-CD20 chimeric monoclonal antibody, rituximab (Rituxan; Genentech, Inc, South San Francisco, CA and IDEC Pharmaceutical Corporation, San Diego, CA), has been evaluated in the treatment of Waldenstrom's macroglobulinemia and multiple myeloma, as well as in nonmalignant plasma cell disorders including IgM polyneuropathies, immune thrombocytopenias, and autoimmune hemolytic anemias, with reported activity in these entities.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP309473.RABMbVfMkRilsL8AoJLv0eUnW-EU4u8YKyuSCmyHsU9k4130_provenance.
- NP309473.RABMbVfMkRilsL8AoJLv0eUnW-EU4u8YKyuSCmyHsU9k4130_assertion evidence source_evidence_literature NP309473.RABMbVfMkRilsL8AoJLv0eUnW-EU4u8YKyuSCmyHsU9k4130_provenance.
- NP309473.RABMbVfMkRilsL8AoJLv0eUnW-EU4u8YKyuSCmyHsU9k4130_assertion SIO_000772 11226004 NP309473.RABMbVfMkRilsL8AoJLv0eUnW-EU4u8YKyuSCmyHsU9k4130_provenance.
- NP309473.RABMbVfMkRilsL8AoJLv0eUnW-EU4u8YKyuSCmyHsU9k4130_assertion wasDerivedFrom befree-2016 NP309473.RABMbVfMkRilsL8AoJLv0eUnW-EU4u8YKyuSCmyHsU9k4130_provenance.
- NP309473.RABMbVfMkRilsL8AoJLv0eUnW-EU4u8YKyuSCmyHsU9k4130_assertion wasGeneratedBy ECO_0000203 NP309473.RABMbVfMkRilsL8AoJLv0eUnW-EU4u8YKyuSCmyHsU9k4130_provenance.